New U.S. Patent Allowance Granted to AXIM® Biotechnologies for Suppository Formulations Comprised of Cannabinoids NEW YORK, Oct. 23, 2018 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM® Biotech” or “AXIM”) (OTCQB: AXIM), a world leader in cannabinoid research and development, today announced that the...

AXIM® Biotechnologies, Inc. Secures Funding to Continue Pharmaceutical Clinical Trials Program in Cannabinoid Research and Development for Multiple Indications NEW YORK, Oct. 26, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company has...

Medical Marijuana, Inc. Investment – AXIM Biotech – Lays Out Powerhouse IP Pipeline, Cannabinoid R&D in Interview SAN DIEGO, Feb. 25, 2016 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM® Biotechnologies,...

AXIM Biotech Leads Cannabis Industry in Cannabinoid Research, Development and Intellectual Property; Tackles 15 Debilitating Conditions With No Known Cure NEW YORK, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies, Inc. (OTC:AXIM) shares the hemp innovator’s vision and...